Product News from the May 20 MM&M News Brief

Share this article:

Product News
The FDA granted traditional approval status to GlaxoSmithKline's Trizivir (abacavir sulfate, lamivudine and zidovudine) for the treatment of HIV infection. Trizivir is the first and only FDA-approved, fixed-dose-combination drug for HIV that combines three drugs into one tablet, GSK said.

Roche has decided to discontinue the sale and distribution of its HIV medication Fortovase (saquinavir), as clinical demand for the drug has declined significantly due to the availability of a new formulation of Invirase (saquinavir mesylate). The removal of Fortovase, which will be discontinued during the first quarter of 2006, is completely voluntary and is not due to safety or efficacy issues, Roche said.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.